Zai Lab Limited (ZLAB) Stock Analysis

Q: What is the ZLAB stock price target?

Take-profit $30.75 (+41.6% upside). Prior stop was $20.19.

Q: What are the risks of investing in ZLAB?

Concentration risk — Geographic: mainland China; Quality below floor (2.0 < 4.0); Quality below floor (2.0 < 4.0); Momentum score 3.5/10 — below 4.5 minimum.

Q: Is ZLAB overvalued or undervalued?

Zai Lab Limited trades at a P/E of N/A (forward -13.9). TrendMatrix value score: 8.2/10. Overall verdict: Sell.

Q: What do analysts say about ZLAB?

14 analysts cover ZLAB with a consensus score of 3.9/5. Average price target: $35.

Range Bound setup

SellVALUE-TRAP 1/5Moderate ConfidenceUpdated 2026-04-30

Healthcare · Biotechnology

Earnings in 7 days (2026-05-07). Expect elevated volatility around the report — consider waiting for post-earnings price action before new entries.

Sell if holding. Engine safety override at $21.71: Quality below floor (2.0 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.1/10 and A.R:R 4.0:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Negative price momentum; Below long-term trend.

Zai Lab is a commercial-stage biopharmaceutical company with seven approved products marketed in Greater China, focused on oncology, immunology, neuroscience, and infectious disease. All commercial operations are in mainland China; products are primarily in-licensed from global... Read more

$21.71+41.6% A.UpsideScore 5.1/10#70 of 158 Biotechnology

Stop $20.19Target $30.75(analyst − 13%)A.R:R 4.0:1

Analyst target$35.34+62.8%12 analysts

$30.75our TP

$21.71price

$35.34mean

$53

Passes 5/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA) and earnings proximity 7d<=7d. Suitability: aggressive.

Thesis

Rewards

No bull case signals

Risks

Concentration risk — Geographic: mainland China

Quality below floor (2.0 < 4.0)

Key Metrics

P/E (TTM)—

P/E (Fwd)-13.9

Mkt Cap$2.3B

EV/EBITDA-104.9

Profit Mgn-38.1%

ROE-22.6%

Rev Growth17.0%

Beta0.86

DividendNone

Rating analysts14

Quality Signals

Piotroski F4/9

Options Flow

P/C1.22bearish

IV78%elevated

Max Pain$18-19.4% vs spot

Concentration Risks(10-K Item 1A)

HIGHGeographicmainland China
10-K Item 1A: 'A substantial portion of our operations, and all of our commercial operations, are conducted in mainland China'

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

2 floor-breakers

Overall = weighted sum of the 10 dimension scores. Fundamentals (Value/Quality/Growth) carry 45%; market signals (Momentum/Sentiment/Insider/Peer) carry 40%; structure (Technical/Risk/Catalyst) carries 15%.

DimensionScoreWeightContribution

Value8.215%1.23

Quality2.015%0.30

Growth6.815%1.02

Momentum3.510%0.35

Sentiment7.910%0.79

Insider Activity3.610%0.36

Peer Rank4.010%0.40

Technical Setup4.35%0.21

Risk Profile4.55%0.23

Catalyst4.15%0.20

Overall (Σ contributions)5.09

Small float-rounding may cause last-digit differences between this sum and the displayed Overall.

Unprofitable operations — net margin -38.1%. Quality floor flags this regardless of sector context.static

Roe

0.0

Roa

0.0

Gross Margin

0.0

Operating Margin

0.0

Net Margin

0.0

Fcf Quality

0.0

Piotroski F

4.4

Moat

5.0

Current Ratio

8.3

Cash-burning: FCF -20% of revenueNo competitive moatQuality concerns

Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static

Macd

0.0

Volume

0.0

Ma Position

3.0

Rsi

4.5

Obv

10.0

Volume accumulation (rising OBV)Below 200-MA, MA slope -8.6%/30d — confirmed downtrend

GatesMomentum 3.5<4.5Death cross (50MA < 200MA)EARNINGS PROXIMITY 7d<=7dA.R:R 4.0 ≥ 1.5Insider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTSEMI CYCLE PEAK CLEARRange BoundSuitability: Aggressive

RSI

54 · Neutral

↓ 20D MA↑ 50D MA↓ 200D MADEATH CROSSSupport $19.84Resistance $25.28

Price Targets

$20

$31

A.Upside+41.6%

A.R:R4.0:1

Position Sizing

ConvictionNone

Suggested %0.5%

Max %1%

RegimeSteady

Risk Alerts

! Quality below floor (2.0 < 4.0)

! Momentum score 3.5/10 — below 4.5 minimum

! Death cross — 50-day MA below 200-day MA

Earnings

2/4 beats

Next Earnings2026-05-07 (7d)

Verdict History

reverse chrono — latest first

Loading history...

Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.

Frequently Asked Questions

Is ZLAB stock a buy right now?

Sell if holding. Engine safety override at $21.71: Quality below floor (2.0 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.1/10 and A.R:R 4.0:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Negative price momentum; Below long-term trend. Chart setup: RSI 54 mid-range, Bollinger mid-band. Prior stop was $20.19. Score 5.1/10, moderate confidence.

What is the ZLAB stock price target?

Take-profit target: $30.75 (+41.6% upside). Prior stop was $20.19. Stop-loss: $20.19.

What are the risks of investing in ZLAB?

Concentration risk — Geographic: mainland China; Quality below floor (2.0 < 4.0).

Is ZLAB overvalued or undervalued?

Zai Lab Limited trades at a P/E of N/A (forward -13.9). TrendMatrix value score: 8.2/10. Verdict: Sell.

What do analysts say about ZLAB?

14 analysts cover ZLAB with a consensus score of 3.9/5. Average price target: $35.

What does Zai Lab Limited do?Zai Lab is a commercial-stage biopharmaceutical company with seven approved products marketed in Greater China, focused...